CME/CE Podcast: Personalizing ADHD Management Using MPH

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:https://www.mycme.com/courses/personalizing-adhd-management-using-methylphenidate-10448SummaryEffective ADHD management demands more than symptom control—it requires personalized treatment strategies aligned with the patient’s unique daily functional needs. Through clinical case examples and pharmacologic comparisons, learners will explore how tailoring treatment using immediate-release (IR), extended-release (ER), and delayed-release/extended-release (DR/ER) methylphenidate (MPH) formulations can optimize symptom control aligned with patients’ daily routines and responsibilities. In this podcast/webcast activity, Joel Young, MD, and Jo Hughes, DMSc, PA-C, CAQ-PSY will highlight practical strategies for implementing personalized ADHD treatment plans, with a focus on the unique benefits of evening-dosed DR/ER-MPH in addressing early-morning and evening functional impairments.This podcast was recorded and is being used with permission of the presenters.Learning ObjectivesEvaluate the pharmacokinetic (PK) and pharmacodynamic (PD) profiles of ER-, DR/ER-, and IR-MPH formulations to implement safe, effective, and personalized ADHD treatment decisions.Discuss individualization of ADHD treatment plans by selecting MPH formulations based on PK profiles, patient characteristics, and functional goals to optimize symptom control and adherence.This activity is accredited for CME/CE CreditThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association for Continuing Education (NACE) and GlobalHealthXchange. NACE is accredited by the ACCME to provide continuing medical education for physicians.The National Association for Continuing Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners® (AANP) through the joint providership of the National Association for Continuing Education (NACE) and GlobalHealthXchange. NACE is accredited by the AANP as an approved provider of nurse practitioner continuing education. Provider number 121222. This activity is approved for 0.50 contact hours (which includes 0.50 hours of pharmacology).For additional information about the accreditation of this program, please contact NACE at [email protected] of Individual DisclosuresPlease review faculty and planner disclosures here.Disclosure of Commercial SupportThis educational activity is supported by an educational grant from Collegium Pharmaceutical, Inc.Please visit  http://naceonline.com to engage in more live and on demand CME/CE content.